Benign Prostatic Hyperplasia Market Forecast

DelveInsight’s Benign Prostatic Hyperplasia Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NV, UNITED STATES, February 3, 2025 /EINPresswire.com/ --
DelveInsight’s “Benign Prostatic Hyperplasia Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Benign Prostatic Hyperplasia, historical and forecasted epidemiology as well as the Benign Prostatic Hyperplasia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Benign Prostatic Hyperplasia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Benign Prostatic Hyperplasia Market Forecast

Some of the key facts of the Benign Prostatic Hyperplasia Market Report:
• The Benign Prostatic Hyperplasia market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
• In May 2024, Sumitomo Pharma America (SMPA) announced that the FDA has accepted its supplemental New Drug Application (sNDA) for GEMTESA (vibegron) to treat overactive bladder (OAB) symptoms in men undergoing pharmacological therapy for BPH. If approved, vibegron would become the first and only beta-3 agonist for this indication. Under the Prescription Drug User Fee Act (PDUFA), the FDA is expected to reach a decision by the third quarter of FY2024
• The alpha blockers approved by the US FDA include terazosin (HYTRIN), doxazosin (CARDURA), tamsulosin (FLOMAX), alfuzosin (UROXATRAL), and silodosin (RAPAFLO).
• The key driver of the BPH market's growth is the increasing prevalence of risk factors such as obesity, cardiovascular diseases, type 2 diabetes, and the rising aging population.
• Benign prostatic hyperplasia is the most prevalent prostate condition among men over 50.
• Among the seven major markets (7MM), the United States had the highest total prevalence of BPH.
• According to DelveInsight's analysis, nearly 80% of men over the age of 80 experience lower urinary tract symptoms due to benign prostatic hyperplasia.
• Key Benign Prostatic Hyperplasia Companies: Blue Water Biotech, Sumitomo Pharma, Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Organon and Co, Nymox Corporation, and others
• Key Benign Prostatic Hyperplasia Therapies: ENTADFI (finasteride and tadalafil), GEMTESA (vibegron), DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, MK0906, NX-1207, Tamsulosin, and others
• The Benign Prostatic Hyperplasia epidemiology based on age-specific cases analyzed that Benign Prostatic Hyperplasia is more common in older males as compared to those below 40 years
• The Benign Prostatic Hyperplasia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Benign Prostatic Hyperplasia pipeline products will significantly revolutionize the Benign Prostatic Hyperplasia market dynamics.

Benign Prostatic Hyperplasia Overview
Benign prostatic hyperplasia (BPH), also known as prostate gland enlargement, is a common condition that affects aging men. It occurs when the prostate gland, which surrounds the urethra (the tube that carries urine from the bladder out of the body), gradually enlarges. The prostate gland's enlargement can cause compression of the urethra, leading to various urinary symptoms.

Get a Free sample for the Benign Prostatic Hyperplasia Market Report:
https://www.delveinsight.com/report-store/benign-prostatic-hyperplasia-bph-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Benign Prostatic Hyperplasia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Benign Prostatic Hyperplasia Epidemiology Segmentation:
The Benign Prostatic Hyperplasia market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
• Total Prevalence of Benign Prostatic Hyperplasia
• Prevalent Cases of Benign Prostatic Hyperplasia by severity
• Gender-specific Prevalence of Benign Prostatic Hyperplasia
• Diagnosed Cases of Episodic and Chronic Benign Prostatic Hyperplasia

Download the report to understand which factors are driving Benign Prostatic Hyperplasia epidemiology trends @ Benign Prostatic Hyperplasia Epidemiology Forecast

Benign Prostatic Hyperplasia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Benign Prostatic Hyperplasia market or expected to get launched during the study period. The analysis covers Benign Prostatic Hyperplasia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Benign Prostatic Hyperplasia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Benign Prostatic Hyperplasia Therapies and Key Companies
• ENTADFI (finasteride and tadalafil): Blue Water Biotech
• GEMTESA (vibegron): Sumitomo Pharma
• DKF0313: Dongkook Pharmaceutical
• Vibegron: Urovant Sciences
• AUS-131 (S-equo): Ausio Pharmaceuticals
• GI198745: GlaxoSmithKline
• DKF-313: Dongkook Pharma
• Silodosin: RECORDATI GROUP
• ASP4901: Astellas Pharma Inc
• Tadalafil: Eli Lilly and Company
• PRX302: Sophiris Bio Corp
• Silodosin: JW Pharmaceutical
• Levitra (Vardenafil, BAY38-9456): Bayer
• WC3055: Warner Chilcott
• Afalaza: Materia Medica Holding
• S-equol: Ausio Pharma
• MK0906: Organon and Co
• NX-1207: Nymox Corporation
• Tamsulosin: GlaxoSmithKline

Scope of the Benign Prostatic Hyperplasia Market Report
• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Benign Prostatic Hyperplasia Companies: Blue Water Biotech, Sumitomo Pharma, Dongkook Pharmaceutical, Urovant Sciences, Ausio Pharmaceuticals, GlaxoSmithKline, RECORDATI GROUP, Astellas Pharma Inc, Eli Lilly and Company, Sophiris Bio Corp, JW Pharmaceutical, Bayer, Warner Chilcott, Materia Medica Holding, Ausio Pharma, Organon and Co, Nymox Corporation, and others
• Key Benign Prostatic Hyperplasia Therapies: ENTADFI (finasteride and tadalafil), GEMTESA (vibegron), DKF0313, Vibegron, AUS-131 (S-equo), GI198745, DKF-313, Silodosin, ASP4901, Tadalafil, PRX302, Silodosin, Levitra (Vardenafil, BAY38-9456), WC3055, Afalaza, S-equol, MK0906, NX-1207, Tamsulosin, and others
• Benign Prostatic Hyperplasia Therapeutic Assessment: Benign Prostatic Hyperplasia current marketed and Benign Prostatic Hyperplasia emerging therapies
• Benign Prostatic Hyperplasia Market Dynamics: Benign Prostatic Hyperplasia market drivers and Benign Prostatic Hyperplasia market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Benign Prostatic Hyperplasia Unmet Needs, KOL’s views, Analyst’s views, Benign Prostatic Hyperplasia Market Access and Reimbursement

To know more about Benign Prostatic Hyperplasia companies working in the treatment market, visit @ Benign Prostatic Hyperplasia Clinical Trials and Therapeutic Assessment

Table of Contents
1. Benign Prostatic Hyperplasia Market Report Introduction
2. Executive Summary for Benign Prostatic Hyperplasia
3. SWOT analysis of Benign Prostatic Hyperplasia
4. Benign Prostatic Hyperplasia Patient Share (%) Overview at a Glance
5. Benign Prostatic Hyperplasia Market Overview at a Glance
6. Benign Prostatic Hyperplasia Disease Background and Overview
7. Benign Prostatic Hyperplasia Epidemiology and Patient Population
8. Country-Specific Patient Population of Benign Prostatic Hyperplasia
9. Benign Prostatic Hyperplasia Current Treatment and Medical Practices
10. Benign Prostatic Hyperplasia Unmet Needs
11. Benign Prostatic Hyperplasia Emerging Therapies
12. Benign Prostatic Hyperplasia Market Outlook
13. Country-Wise Benign Prostatic Hyperplasia Market Analysis (2020–2034)
14. Benign Prostatic Hyperplasia Market Access and Reimbursement of Therapies
15. Benign Prostatic Hyperplasia Market Drivers
16. Benign Prostatic Hyperplasia Market Barriers
17. Benign Prostatic Hyperplasia Appendix
18. Benign Prostatic Hyperplasia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora
DelveInsight Business Research
+1 469-945-7679
email us here

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.